2018
A framework to rank genomic alterations as targets for cancer precision medicine: the ESMO Scale for Clinical Actionability of molecular Targets (ESCAT)
Mateo J, Chakravarty D, Dienstmann R, Jezdic S, Gonzalez-Perez A, Lopez-Bigas N, Ng CKY, Bedard PL, Tortora G, Douillard J, Van Allen EM, Schultz N, Swanton C, André F, Pusztai L. A framework to rank genomic alterations as targets for cancer precision medicine: the ESMO Scale for Clinical Actionability of molecular Targets (ESCAT). Annals Of Oncology 2018, 29: 1895-1902. PMID: 30137196, PMCID: PMC6158764, DOI: 10.1093/annonc/mdy263.Peer-Reviewed Original ResearchConceptsESMO ScaleMolecular targetsClinical actionabilityPrecision Medicine Working GroupGenomic alterationsPrecision medicineRoutine clinical decisionEvidence-based criteriaMedicine Working GroupLack of evidencePreclinical evidenceClinical benefitClinical evidencePatient populationClassification systemClinical managementCancer precision medicineInvestigational targetsPatient managementMolecular aberrationsTumor typesClinical decisionClinical targetsAvailable evidenceEuropean Society
2015
Immunotherapy opportunities in breast cancer.
Pusztai L, Ladányi A, Székely B, Dank M. Immunotherapy opportunities in breast cancer. Magyar Onkológia 2015, 60: 34-40. PMID: 26934349.Peer-Reviewed Original ResearchConceptsAnti-tumor immune responseLocal anti-tumour immune responseBreast cancerImmune responseClinical trialsEffective immune checkpoint inhibitorsEarly-stage breast cancerTriple-negative breast cancerPhase I clinical trialImmune checkpoint inhibitorsTumor response rateExtensive lymphocytic infiltrationPD-L1 antibodiesDirect clinical evidenceBreast cancer patientsStage breast cancerNew treatment modalitiesNegative breast cancerCheckpoint inhibitorsChemotherapy regimensMetastatic settingNeoadjuvant chemotherapyLymphocytic infiltrationClinical benefitClinical evidence